BLINCYTO
35mcgBLINCYTO35mcg
BLINCYTO (Blinatumomab) 35mcg is a first-in-class BiTE® antibody by Amgen for B-cell precursor acute lymphoblastic leukemia (ALL).
Key Benefits
- First-in-class BiTE® antibody — revolutionary mechanism of action
- Significantly improved OS vs chemotherapy (TOWER trial: 7.7 vs 4.0 months)
- High MRD response rate (78% in BLAST trial)
- Practice-changing E1910 results in frontline ALL
- Off-the-shelf availability (no manufacturing delay like CAR-T)
- Active at picomolar concentrations
Contact Us for Pricing
Get a written quote against a prescription within 24 hours for BLINCYTO 35mcg. Our team is available 24/7.
Direct line: +44 7429 917553
Prescription required
We do not proceed without one
Licensed Türkiye channels
İTS serial-traceable by karekod
Delivered in person
Not shipped by courier
Written reply
Quote within 24 hours
How BLINCYTO Works
Blinatumomab is a BiTE® (bispecific T-cell engager) antibody construct consisting of two single-chain variable fragments (scFv) connected by a short linker peptide. One scFv binds to CD19 on B-cell leukemia cells, while the other binds to CD3 on T-cells.
By simultaneously binding both targets, blinatumomab creates a direct immunological synapse between the patient's T-cells and the cancer cells. This activates endogenous T-cell cytotoxicity, leading to lysis of CD19-positive leukemic blasts through perforin/granzyme-mediated killing.
This mechanism is unique because it bypasses MHC-restricted antigen presentation, enabling potent anti-leukemic activity at picomolar concentrations. The small size of the BiTE construct (~55 kDa) also allows it to bridge cells more efficiently than conventional antibodies.
About BLINCYTO 35mcg
BLINCYTO (blinatumomab) 35mcg powder for solution for infusion by Amgen is the world's first bispecific T-cell engager (BiTE®) antibody approved for clinical use. It represents a revolutionary approach to immunotherapy by redirecting the patient's own T-cells to recognize and destroy CD19-positive leukemic cells. Blincyto is approved for relapsed or refractory B-cell precursor ALL in adults and children, and for ALL in first or second complete remission with minimal residual disease (MRD) ≥0.1%. The landmark TOWER trial demonstrated significant overall survival benefit, and the E1910/ECOG trial established Blincyto as part of frontline ALL treatment. Working through licensed Turkish pharmacy channels, we provide authentic Amgen BLINCYTO with validated cold chain shipping (2-8°C), batch and expiry documentation, and a written quote against a prescription, usually within 24 hours for hospitals and hematology centers worldwide.
Common Uses
- Relapsed or refractory Ph- B-cell precursor ALL (adults and children)
- Ph- B-cell precursor ALL in CR1/CR2 with MRD ≥0.1%
- Frontline ALL consolidation (per E1910 data)
Dosage Information
BLINCYTO dosing varies by indication:
Relapsed/Refractory ALL (Adults ≥45kg):
MRD-Positive ALL:
Administered as continuous intravenous infusion over 24 hours using an infusion pump. Each vial contains 35 mcg blinatumomab.
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store at 2-8°C (36-46°F). Do not freeze. Protect from light. Store in original packaging. After reconstitution: stable up to 96 hours at 2-8°C or 48 hours at room temperature (≤27°C). Validated cold chain required for shipping.
We ensure proper cold chain handling during shipping to maintain product integrity.
Full prescribing monograph
A single reference page compiled from the manufacturer's prescribing information and the regulator's public product data. No pricing is published on it.
Frequently Asked Questions About BLINCYTO
Find answers to common questions about ordering, pricing, and shipping.
Related Oncology Medications Products
Explore more oncology medications medications from our catalog
